Camille MacMillin/STAT

New infant botulism outbreak puts fancy formulas under scrutiny

Parents and experts ask if premium, organic, whole-milk baby formulas entering the market have outpaced the science and regulations needed to ensure safety.

By Sarah Todd

STAT+ | Senate Democrats demand HHS provide records on federal vaccine policy

Senate Democrats issue document demands for Trump administration vaccine policy changes, including RFK Jr.'s controversial restructuring of the ACIP panel.

By Daniel Payne

Super-potent synthetic opioids called nitazenes are spreading across the U.S.

More potent than fentanyl, nitazenes are flooding the U.S. market. Co-published with investigative outlet Bellingcat, a deep dive into a lethal new danger.

By Jonathan Moens — Bellingcat

Kevork Djansezian/Getty Images

STAT+ | In pancreatic cancer, Patrick Soon-Shiong makes promises he has not kept

In this week's edition of "Adam's Biotech Scorecard," Adam also weighs in on Abivax as it tries again to squelch cancer-risk fears about its therapy.

By Adam Feuerstein

RFK Jr. presents $700 million in mental health funding, but experts say grants aren’t new

Touted as a Trump administration accomplishment, experts question whether the mental health and addiction funds are new or just reallocated existing grants.

By Lev Facher

STAT+ | Eli Lilly ends 340B drug discounts to some hospitals for failing to provide claims data

Lilly is taking this step in a bid to reduce what it calls "duplicate discounts" paid to many large hospital systems.

By Ed Silverman and Tara Bannow

STAT

What’s next for GLP-1 weight loss drugs?

Pfizer, Amgen look to compete with Novo Nordisk and Eli Lilly for lucrative weight loss drug sales. STATus Report host Alex Hogan looks at shifting market.

By Alex Hogan

New hope in treating Huntington’s disease and a report card on RFK Jr.’s promises

Lauren Holder, a Huntington’s disease advocate who is living with the early stages of the disease, joins the podcast to talk about a new FDA development.

By Elaine Chen, Allison DeAngelis, and Adam Feuerstein